Insulin peglispro
- Generic Name
- Insulin peglispro
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1200440-65-8
- Unique Ingredient Identifier
- 6Y83I5F10I
- Associated Conditions
- -
- Associated Therapies
- -
A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics
- Conditions
- Interventions
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT02197520
- Locations
- ๐บ๐ธ
Profil Institute for Clinical Research Inc, Chula Vista, California, United States
A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements
- Conditions
- Interventions
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT02152384
- Locations
- ๐ฉ๐ช
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany
A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT02132637
- Locations
- ๐บ๐ธ
Profil Institute for Clinical Research Inc, Chula Vista, California, United States
๐ฉ๐ชFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany
A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
- Conditions
- Interventions
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT02109029
- Locations
- ๐ฆ๐น
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Graz, Austria
A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT02106364
- Locations
- ๐บ๐ธ
Diagnostic Rheumatology and Research, Indianapolis, Indiana, United States
๐บ๐ธFlorida Medical Clinic PA, Zephyrhills, Florida, United States
๐บ๐ธHeartland Research Associates, Wichita, Kansas, United States
A Study of Insulin Peglispro in Healthy Male Japanese Participants
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 11
- Registration Number
- NCT01995526
- Locations
- ๐ฏ๐ต
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan
A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment
- Conditions
- Interventions
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 388
- Registration Number
- NCT01894568
- Locations
- ๐จ๐ณ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yongkang City, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.